Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component [MC]). We developed a mathematical model to assess the prognostic value of serum MC...

Descripción completa

Detalles Bibliográficos
Autores: Tamariz-Amador, Luis-Esteban, Rodriguez-Otero, Paula, Jiménez-Ubieto, Ana, Rosiñol, Laura, Oriol, Albert, Rios, Rafael, Sureda, Anna, Blanchard, María-Jesús, Hernández, Miguel-Teodoro, Cabañas Perianes, Valentin, Jarque, Isidro, Bargay Lleonart, Joan, Gironella, Mercedes, de Arriba, Felipe, Palomera, Luis, Gonzalez-Montes, Yolanda, Martí, Josep M, Krsnik, Isabel, Arguiñano, José María, González, María Esther, Casado, Luis Felipe, González-Rodriguez, Ana Pilar, López-Anglada, Lucía, Puig, Noemi, Cedena, Maria Teresa, Paiva, Bruno, Mateos, Maria-Victoria, San Miguel, Jesus F., Lahuerta, Juan-José, Bladé, Joan, Trocóniz, Iñaki F
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/18621
Acceso en línea:https://hdl.handle.net/20.500.13003/18621
Access Level:acceso abierto
Palabra clave:Prognosis
Multiple Myeloma
Neoplasm, Residual
Treatment Outcome
Humans
Antineoplastic Combined Chemotherapy Protocols
Paraproteins
Resultado del Tratamiento
Humanos
Protocolos de Quimioterapia Combinada Antineoplásica
Pronóstico
Mieloma Múltiple
Paraproteínas
Neoplasia Residual
Descripción
Sumario:Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component [MC]). We developed a mathematical model to assess the prognostic value of serum MC response kinetics during 6 induction cycles, in 373 NDMM transplanted patients treated in the GEM2012Menos65 clinical trial. The model calculated a "resistance" parameter that reflects the stagnation in the response after an initial descent. Two patient subgroups were defined based on low and high resistance, that respectively captured sensitive and refractory kinetics, with progression-free survival (PFS) at 5 years of 72% and 59% (HR 0.64, 95% CI 0.44-0.93; P = .02). Resistance significantly correlated with depth of response measured after consolidation (80.9% CR and 68.4% minimal residual disease negativity in patients with sensitive vs. 31% and 20% in those with refractory kinetics). Furthermore, it modulated the impact of reaching CR after consolidation; thus, within CR patients those with refractory kinetics had significantly shorter PFS than those with sensitive kinetics (median 54 months vs. NR; P = .02). Minimal residual disease negativity abrogated this effect. Our study also questions the benefit of rapid responders compared to late responders (5-year PFS 59.7% vs. 76.5%, respectively [P < .002]). Of note, 85% of patients considered as late responders were classified as having sensitive kinetics. This semi-mechanistic modeling of M-component kinetics could be of great value to identify patients at risk of early treatment failure, who may benefit from early rescue intervention strategies.

Similares en LA Referencia